Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy With Omalizumab in Patients With Chronic Idiopathic Spontaneous Urticaria (CIU CSU). J of Skin 2018, 2 (S1), S51. https://doi.org/10.25251/skin.2.supp.51.